Monday, August 24, 2026
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The scientist using AI to hunt for antibiotics just about everywhere

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The scientist using AI to hunt for antibiotics just about everywhere Date: 2026-02-16 11:00 Source: https://www.technologyreview.com/2026/02/16/1132516/cesar-de-la-fuente-using-ai-antibiotics-hunt/ <p>When he was just a teenager trying to decide what to do with his life, César…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • These peptides haven't yet been transformed into usable drugs that help people

    80% confidence
  • It's only been a few years since folks have been using AI meaningfully in drug discovery

    80% confidence
  • The use, overuse, and misuse of antibiotics drives antimicrobial resistance

    80% confidence
  • De la Fuente is marvelously talented, very innovative

    80% confidence
  • De la Fuente has really helped pioneer the space of harnessing AI for real-world problems

    80% confidence
  • Drug discovery in any domain is a statistics game. You need enough shots on goal to happen to get one

    80% confidence
  • This is the world that we live in today, and it's incredible

    80% confidence
  • AI has already saved decades of human research time

    80% confidence
  • Antimicrobial resistance deaths could surge past 8 million by 2050

    80% confidence
  • Many companies that attempted antibiotic development have folded because there's no good return on investment

    80% confidence
  • Researchers have moved from using predictive models to developing generative approaches

    80% confidence
  • Antimicrobial resistance is an almost impossible problem

    80% confidence
  • The world of antibiotic development needs as much creativity and innovation as researchers can muster

    80% confidence
  • The antibiotic discovery pipeline remains perilously thin, impeded by high development costs, lengthy timelines, and low returns on investment

    80% confidence
  • Biology is an information source like a bunch of code

    80% confidence

Cited in these Via News reports